Did Reduced 2025 Losses and NDA Plans Just Shift Immunome's (IMNM) Investment Narrative? [Yahoo! Finance]
Immunome, Inc. (IMNM)
Company Research
Source: Yahoo! Finance
A key angle for investors is how reduced losses alongside an expanded late-stage cancer portfolio and potential future equity issuance could shape Immunome's financial and operational flexibility. Next, we will examine how Immunome's reduced net loss and plans to file a New Drug Application influence its broader investment narrative. The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. What Is Immunome's Investment Narrative? To own Immunome, you have to be comfortable backing a high-risk oncology platform where value largely hinges on execution around varegacestat and the broader late-stage pipeline, rather than current fundamentals. The latest results show a narrower full-year net loss of US$212.39 million and lower loss per share, which slightly eases the burn profile but does not change the fact that the company remains deeply unprofitable. The planned New Drug Application
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome: Upcoming NDA, Valuation, And Investment Case [Seeking Alpha]Seeking Alpha
- Immunome (IMNM) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMNM&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "selMarketBeat
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Immunome (IMNM) had its price target raised by Craig Hallum from $33.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
- Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing [Yahoo! Finance]Yahoo! Finance
IMNM
Earnings
- 8/6/25 - Beat
IMNM
Sec Filings
- 3/23/26 - Form 4
- 3/20/26 - Form 144
- 3/12/26 - Form 4
- IMNM's page on the SEC website